- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04169308
Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty
Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty on First Impressions and Quality of Life (FACE-Q Scale)
The purpose of this research is to determine the effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty on First Impressions and Quality of Life determined by using the FACE-Q Scale.
Secondary objectives include:
To determine the efficacy of Restylane-L® Filler injection to the nose in reduction of convexity of the nasal dorsum as measured on pre/post injection 2D photographs.
To measure changes in nasal projection and rotation after injection with Restylane-L® Filler in subset of patients who underwent nasal tip augmentation.
To determine the safety of Restylane-L® Filler injection to the nose for non-surgical rhinoplasty.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- DeNova Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females of ages 21 and above.
- Subjects will be required not to have had previous filler injections, or other cosmetic treatments to the nose within the last 12 months.
- Subjects that understand the purpose and aspects of the study, freely sign the consent and complete the required treatment and follow up visit.
Exclusion Criteria:
- Males and females below age of 21.
- Subjects who have had previous filler injections, or other cosmetic treatments to the nose within the last 12 months.
- Subjects who are pregnant or nursing.
- Subjects with a known allergy or sensitivity to any component of the study ingredients.
- Any history of bleeding disorders (iatrogenic or otherwise). This includes persons who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks.
- Anyone taking aspirin, ibuprofen, St. John's Wort, or high doses of Vitamin E supplements in the last 3 weeks.
- Subjects with diseases, injuries, or disabilities of the nose, including those with autoimmune disease affecting the nose, implants, and previous surgical rhinoplasty.
- Subjects that do not understand the purpose and aspects of the study, do not sign the consent and do not complete the required treatment and follow up visit will also be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Restylane-L® Filler injection
|
Restylane-L® Filler injection into the soft tissue of the nose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the effects of Restylane-L® Filler injection into the nose on first impressions and quality of life based on the validated questionnaires using FACE-Q scales.
Time Frame: 4 weeks
|
We will measure changes in first impressions using a questionnaire with categories which include social skills, academic performance, dating success, occupational success, attractiveness, financial success, relationship success, and athletic skills.
The 300 independent reviewers will grade each photo on a scale of 1(least favorable) to 10 (best).
Evaluation of effects on quality of life will be reported through comparison of pre/post injection quality of life survey scores filled out by patients using the validated FACE-Q PRO survey measure (categories include appraisal of nasal appearance, psychological well-being, social function, and psychological distress).
Maximal reported score is 4 (very satisfied) and lowest reported score is 1 (very dissatisfied).
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the efficacy of Restylane-L® Filler injection to the nose in reduction of convexity of the nasal dorsum as measured on pre/post injection 2D photographs.
Time Frame: 4 weeks
|
Secondary assessment of this study is to determine the efficacy of Restylane-L® filler injection into the nose as defined by the reduction of the nasal dorsal convexity to 0mm (+/- 10% of pre injection value) as measured by differences in length of a line (from pre to post injection photos) from the highest tip of the nasal dorsum to a line drawn from the Radix to the supratip region on a lateral view 2D photograph.
This will be performed through calculation of changes in nasal dorsal hump convexity for all patients.
All measures will be performed in triplicate and the mean of the 3 measures will be used.
|
4 weeks
|
To measure changes in nasal projection and rotation after injection with Restylane-L® Filler in subset of patients who underwent nasal tip augmentation.
Time Frame: 4 weeks
|
Subgroup analysis will be performed for the patients who also underwent augmentation of the nasal tip to measure changes in projection (in mm) and rotation (in degrees) achieved from injection of filler. We will be using the Goode method for measuring nasal projection. We will be reporting the following measurements: Nasal projection is the perpendicular distance between the tip-defining point and a line passing through the nasion and alar crease. Nasal length is the distance between the nasion and the tip-defining point. The ideal Goode ratio of 0.55 to 0.60 is the perpendicular distance between the tip-defining point and a line passing through the nasion and alar crease divided by nasal length. Nasal tip rotation or the nasolabial angle (normal 90-120 degrees), is the angle defined by the columellar point-to-subnasale line intersecting with subnasale-to-labrale superius line. The mean of the 3 measurements in (mm for distance) or (degrees for rotation) will be reported. |
4 weeks
|
To determine the safety of Restylane-L® Filler injection to the nose for non-surgical rhinoplasty by recording the number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 4 weeks
|
The safety profile of injecting Restylane-L® into the nose will be measured by continually monitoring for AEs during the duration of the study and reporting the total number and description of events.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RRFI-2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deformity of Nasal Cartilage
-
Gaziosmanpasa Research and Education HospitalUnknownNasal Deformity | Revision Rhinoplasty | Autogenous Rib Graft | Costal Cartilage | HarvestingTurkey
-
Sewon Cellontech Co., Ltd.UnknownDefect of Articular Cartilage | Articular Cartilage Disorder of Knee | Degeneration; Articular Cartilage, KneeKorea, Republic of
-
Middle East Technical UniversityCompletedOsteoarthritis | Degenerative Lesion of Articular Cartilage of Knee | Articular Cartilage Disorder of KneeTurkey
-
Reconstrata, LLCChildren's Hospital Medical Center, CincinnatiSuspendedMicrotia | Ear Deformities, Acquired | Ear; Deformity, Congenital | Nose Deformity | Nose Deformities, Acquired | Nose; Deformity, Congenital | Nose; Deformity, Congenital, Bent or Squashed | Nose; Deformity, Syphilitic, Congenital | Nose; Deformity, Bone (Nose Cartilage) | Nose; Deformity, Septum, Congenital and other conditionsUnited States
-
University Hospital, Basel, SwitzerlandDeutsche Arthrose-HilfeCompletedDegenerative Lesion of Articular Cartilage of Knee | Cartilage LesionSwitzerland
-
Bezmialem Vakif UniversityCompletedEdema | Rhinoplasty | Nasal DeformityTurkey
-
BioPoly LLCCompletedCartilage Injury | Defect of Articular Cartilage | Cartilage DamageUnited Kingdom
-
KLSMC Stem Cells, Inc.CompletedArticular Cartilage Disorder of Knee | Articular Cartilage; DegenerationUnited States, Malaysia
-
Zimmer Orthobiologics, Inc.TerminatedDefect of Articular Cartilage | Articular Cartilage Disorder | Degeneration; Articular Cartilage | Chronic Cartilage Injury | Acute Cartilage InjuryUnited States
-
Kensey Nash CorporationCompletedAcute Knee Cartilage Injury | Tear of Articular Cartilage of Knee, CurrentUnited Kingdom, Italy, Germany, Netherlands
Clinical Trials on Restylane-L® Filler injection
-
Galderma R&DCompleted
-
Maxigen Biotech Inc.Completed
-
AllerganCompletedSubjects Desiring Lip AugmentationUnited States
-
University of PennsylvaniaGalderma R&DActive, not recruiting
-
Rejuva Medical AestheticsUnknownTear Trough Hollowing, Under Eye BagsUnited States
-
Abington Memorial HospitalGalderma R&DUnknownEsthetic & Topographic Shifts From Facial FillersUnited States
-
University of Southern CaliforniaSofregen Medical, Inc.CompletedDysphonia | Vocal Cord Paralysis Unilateral | Dysphagia, OropharyngealUnited States
-
University of MichiganGalderma R&DNot yet recruiting
-
D.medSeoul National University Hospital; Chung-Ang University Hosptial, Chung-Ang...CompletedNasolabial Fold ImprovementKorea, Republic of
-
DeNova ResearchGalderma R&DCompletedHand RejuvinationUnited States